"Outstanding" ADC Candidates Emerge for SCLC, Other Cancers.

IF 29.5 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2026-08-03 DOI:10.1158/2159-8290.CD-NW2026-0066

引用次数: 0

Abstract

The treatment arsenal for small cell lung cancer could soon include antibody-drug conjugates, with early data from three phase I studies indicating robust response rates to CD56-targeting DXC006, DLL-3-targeting BL-M14D1, and B7-H3-targeting SYS6043. The latter also appears active in other tumor types, including ovarian and breast cancers. As well, phase II findings on a fourth ADC candidate, HER2-targeting trastuzumab brengitecan, suggest its strong efficacy in platinum-resistant ovarian cancer.

查看原文本刊更多论文

“优秀”ADC候选人出现在SCLC和其他癌症。

小细胞肺癌的治疗方法可能很快包括抗体-药物偶联物，三项I期研究的早期数据表明，靶向cd56的dx006、靶向dll -3的BL-M14D1和靶向b7 - h3的SYS6043的应答率很高。后者在其他类型的肿瘤中也很活跃，包括卵巢癌和乳腺癌。此外，第四种ADC候选药物——靶向her2的曲妥珠单抗brengitecan的II期研究结果表明，它对铂耐药卵巢癌有很强的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.